Recent Developments in Peptidyl Diaryl Phoshonates as Inhibitors and Activity-Based Probes for Serine Proteases.

covalent inhibitors enzyme activity imaging phosphonate esters phosphorus peptide analogs

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
10 Jun 2019
Historique:
received: 13 05 2019
revised: 06 06 2019
accepted: 08 06 2019
entrez: 13 6 2019
pubmed: 13 6 2019
medline: 13 6 2019
Statut: epublish

Résumé

This review presents current achievements in peptidyl diaryl phosphonates as covalent, specific mechanism-based inhibitors of serine proteases. Along three decades diaryl phosphonates have emerged as invaluable tools in fundamental and applicative studies involving these hydrolases. Such an impact has been promoted by advantageous features that characterize the phosphonate compounds and their use. First, the synthesis is versatile and allows comprehensive structural modification and diversification. Accordingly, reactivity and specificity of these bioactive molecules can be easily controlled by appropriate adjustments of the side chains and the leaving groups. Secondly, the phosphonates target exclusively serine proteases and leave other oxygen and sulfur nucleophiles intact. Synthetic accessibility, lack of toxicity, and promising pharmacokinetic properties make them good drug candidates. In consequence, the utility of peptidyl diaryl phosphonates continuously increases and involves novel enzymatic targets and innovative aspects of application. For example, conjugation of the structures of specific inhibitors with reporter groups has become a convenient approach to construct activity-based molecular probes capable of monitoring location and distribution of serine proteases.

Identifiants

pubmed: 31185654
pii: ph12020086
doi: 10.3390/ph12020086
pmc: PMC6631691
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Biochem Biophys Res Commun. 2000 Oct 5;276(3):1235-9
pubmed: 11027616
Curr Med Chem. 2005;12(8):971-98
pubmed: 15853709
Bioorg Med Chem Lett. 2006 Jun 1;16(11):2886-90
pubmed: 16546384
Bioorg Med Chem Lett. 2006 Jun 1;16(11):2882-5
pubmed: 16554154
Infect Disord Drug Targets. 2006 Mar;6(1):3-16
pubmed: 16787300
J Med Chem. 2006 Oct 5;49(20):6074-86
pubmed: 17004721
Curr Med Chem. 2009;16(13):1673-87
pubmed: 19442139
Bioconjug Chem. 2009 Nov;20(11):2098-105
pubmed: 19810697
Biochemistry. 1991 Jan 15;30(2):485-93
pubmed: 1988040
Bioorg Med Chem. 2010 Dec 1;18(23):8350-5
pubmed: 21041095
Pharmacol Rev. 2010 Dec;62(4):726-59
pubmed: 21079042
J Viral Hepat. 2011 May;18(5):305-15
pubmed: 21470343
Anal Biochem. 2012 Feb 15;421(2):667-72
pubmed: 22178917
Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6229-34
pubmed: 22474388
J Med Chem. 2012 Jul 26;55(14):6541-53
pubmed: 22720718
Bioorg Med Chem Lett. 2012 Sep 1;22(17):5574-8
pubmed: 22858096
Curr Pharm Des. 2013;19(6):1154-78
pubmed: 23016683
Curr Pharm Des. 2013;19(6):1126-53
pubmed: 23016690
Nat Rev Drug Discov. 2012 Oct;11(10):777-89
pubmed: 23023677
Bioorg Med Chem Lett. 2013 Mar 1;23(5):1412-5
pubmed: 23357627
J Biol Chem. 2013 Jul 26;288(30):21473-81
pubmed: 23775089
Org Biomol Chem. 2013 Sep 14;11(34):5714-21
pubmed: 23884325
Int J Med Microbiol. 2014 Jan;304(1):23-30
pubmed: 24119566
Protein Sci. 2014 Feb;23(2):179-89
pubmed: 24375505
Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2518-23
pubmed: 24550277
Nucl Med Biol. 2014 Jul;41(6):477-87
pubmed: 24768145
Annu Rev Biochem. 2014;83:249-73
pubmed: 24905783
J Clin Invest. 2014 Oct;124(10):4445-58
pubmed: 25180606
Chembiochem. 2014 Nov 24;15(17):2605-12
pubmed: 25236966
J Biol Chem. 2014 Nov 14;289(46):31777-91
pubmed: 25288799
Curr Opin Microbiol. 2015 Feb;23:42-8
pubmed: 25461571
Org Biomol Chem. 2015 Feb 28;13(8):2293-9
pubmed: 25553959
Mol Cell Proteomics. 2015 Aug;14(8):2177-93
pubmed: 26041847
PLoS One. 2015 Jul 14;10(7):e0132818
pubmed: 26172376
ChemMedChem. 2015 Oct;10(10):1641-6
pubmed: 26306030
Biopolymers. 2016 Nov 4;106(4):521-30
pubmed: 26615968
Bioorg Med Chem Lett. 2016 May 1;26(9):2210-3
pubmed: 27020301
Chemistry. 2016 Jun 13;22(25):8525-35
pubmed: 27214780
PLoS One. 2016 Jul 26;11(7):e0159868
pubmed: 27459298
Curr Opin Pharmacol. 2016 Oct;30:84-92
pubmed: 27544488
Contrast Media Mol Imaging. 2016 Nov;11(6):448-458
pubmed: 27558262
Bioorg Med Chem Lett. 2017 Jan 15;27(2):254-260
pubmed: 27923620
Antiviral Res. 2017 Mar;139:88-94
pubmed: 28034744
FEBS J. 2017 May;284(10):1518-1539
pubmed: 28052575
Chemistry. 2017 Apr 19;23(22):5205-5209
pubmed: 28370501
J Am Chem Soc. 2017 Jul 26;139(29):10115-10125
pubmed: 28672107
Antiviral Res. 2017 Aug;144:286-298
pubmed: 28673801
J Med Chem. 2018 Mar 8;61(5):1858-1870
pubmed: 29442501
ACS Med Chem Lett. 2018 Mar 04;9(4):345-350
pubmed: 29670698
J Enzyme Inhib Med Chem. 2019 Dec;34(1):8-14
pubmed: 30362835
J Med Chem. 2019 Jan 24;62(2):774-797
pubmed: 30571121
J Enzyme Inhib. 1994;8(3):147-58
pubmed: 7539484
Methods Enzymol. 1994;244:423-41
pubmed: 7845224
Bioconjug Chem. 1994 Sep-Oct;5(5):400-5
pubmed: 7849068
Biochemistry. 1996 Mar 12;35(10):3147-55
pubmed: 8605148

Auteurs

Marta Maślanka (M)

Department of Bioorganic Chemistry, Wrocław University of Science and Technology, Wybrzeże Wyspiańskiego 27, 50-370 Wrocław, Poland. 217458@student.pwr.edu.pl.

Artur Mucha (A)

Department of Bioorganic Chemistry, Wrocław University of Science and Technology, Wybrzeże Wyspiańskiego 27, 50-370 Wrocław, Poland. artur.mucha@pwr.edu.pl.

Classifications MeSH